 |
|
|
| |
Noninvasive Tests of Fibrosis and Risk of Liver-Related Complications: Lessons From Patients
With HCV Cirrhosis Following Successful Sofosbuvir-Based Treatment
|
| |
| |
EASL 2020 Aug 27-29 virtual
Reported by Jules Levin
K. Rajender Reddy,1 Andrew J. Muir,2 Susanna Naggie,2 Eric J. Lawitz,3 Edward Gane,4 Brian Conway,5 Peter J. Ruane,6 Ziad Younes,7 Frances Chen,8 Marianne Camargo,8 Anuj Gaggar,8 Robert P. Myers,8 Anand P. Chokkalingam,8 Barbara Leggett,9 Jose Luis Calleja,10 Kosh Agarwal,11 Ira Jacobson,12 Alessandra Mangia13
1University of Pennsylvania, Philadelphia, USA; 2Duke University, Durham, North Carolina, USA; 3Texas Liver Institute, UT Health San Antonio, Texas, USA; 4New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand; 5Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada; 6Ruane Medical & Liver Health Institute, Los Angeles, California, USA; 7Gastro One, Germantown, Tennessee, USA; 8Gilead Sciences, Inc., Foster City, California; 9The University of Queensland Faculty of Medicine, Brisbane, Australia; 10Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; 11Kings College Hospital, London, UK; 12NYU Langone Health, New York, New York, USA; 13Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
*LS by TE <9.5 kPa = F0-2, 9.6-12.5 kPa = F3, and >12.5 kPa = F4; Cumulative; events that occurred prior to registry start date were excluded; Cumulative; includes bleeding varices, SB peritonitis, hepatic hydrothorax, ascites, hepatic encephalopathy, liver transplant, HCC, and liver-related death; events that occurred prior to registry start date were excluded.
References: 1. Castera L, et al. Gastroenterology 2005;128:343-50; 2. Parkes J, et al. J Viral Hepat 2011;18:23-31; 3. Peters MG, et al. AIDS 2016;30:723-9; 4. Vergniol J, et al. Gastroenterology 2011;140:1970-9.
Acknowledgments: We extend our thanks to the patients and their families. This study was funded by Gilead Sciences, Inc.
|
| |
|
|
|
|
|
